• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Metagenomi Inc.

    3/17/25 4:16:42 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGX alert in real time by email
    S-8 1 mgx-20250317.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 17, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    Metagenomi, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    81-3909017

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    Metagenomi, Inc.

    5959 Horton Street, 7th Floor

    Emeryville, California 94608

    (510) 871-4880

    (Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

     

    Metagenomi, Inc. 2024 Stock Option and Incentive Plan

    Metagenomi, Inc. 2024 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Brian C. Thomas, Ph.D.

    Chief Executive Officer

    Metagenomi, Inc.

    5959 Horton Street, 7th Floor

    Emeryville, California 94608

    (510) 871-4880

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Mitchell S. Bloom

    Edwin M. O’Connor

    Justin S. Platt

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering (a) an additional 1,870,923 shares of common stock, par value $0.0001 per share (“Common Stock”), of Metagenomi, Inc. (the “Registrant”) available for issuance under the Registrant’s 2024 Stock Option and Incentive Plan (the “2024 Plan”), which were added on January 1, 2025 pursuant to an “evergreen” provision therein, and (b) an additional 374,184 shares of Common Stock of the Registrant available for issuance under the Registrant’s 2024 Employee Stock Purchase Plan (the “2024 ESPP”), which were added on January 1, 2025 pursuant to an “evergreen” provision therein, for which a Registration Statement on Form S-8 relating to the same employee benefit plans are effective.

     

    These additional shares of Common Stock are of the same class as the other securities for which the Registrant’s Registration Statement on Form S-8 (File No. 333-276983) filed with the Securities and Exchange Commission (“Commission”) on February 9, 2024 is effective.

     

    Pursuant to General Instruction E to Form S-8, the contents of the Registration Statement on Form S-8 filed by the Registrant on February 9, 2024 (File No. 333-276983) related to the 2024 Plan and the 2024 ESPP are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.

     

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Commission:

    (a)
    The Registration’s Annual Report on Form 10-K filed with the Commission on March 17, 2025;
    (b)
    The Registrant’s Current Reports on Form 8-K filed with the Commission on January 16, 2025 and March 17, 2025; and
    (c)
    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-41949), filed by the Registrant with the Commission on February 5, 2024, including any amendments or reports filed for the purpose of updating such description.

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Under no circumstances will any information furnished under current items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

     


     

    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Exhibit Table

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on February 13, 2024 (File No. 001-41949)).

     

     

     

    4.2

     

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on February 13, 2024 (File No. 001-41949)).

     

     

     

    4.3

     

    Registration Rights Agreement among the Registrant and certain of its stockholders, dated January 24, 2024 (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-276413)).

     

     

     

    4.4

     

    Form of Common Stock Certificate (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-276413)).

     

     

     

    5.1*

     

    Opinion of Goodwin Procter LLP.

     

     

     

    23.1*

     

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

     

     

     

    23.2*

     

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

     

    24.1*

     

    Power of Attorney (included on signature page).

     

     

     

    99.1

     

    Metagenomi, Inc. 2024 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-276413)).

     

     

     

    99.2

     

    Metagenomi, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-276413)).

     

     

     

    107*

     

    Filing fee table.

     

    * Filed herewith.

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on this 17th day of March, 2025.

     

     

     

    Metagenomi, Inc.

     

     

    By:

    /s/ Brian C. Thomas

     

    Brian C. Thomas, Ph.D.

    Chief Executive Officer and Director

     

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Brian C. Thomas and Pamela Wapnick, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    NAME

    TITLE

    DATE

    /s/ Brian C. Thomas

    Chief Executive Officer and Director

    March 17, 2025

    Brian C. Thomas, Ph.D.

    (Principal Executive Officer)

    /s/ Pamela Wapnick

    Chief Financial Officer

    March 17, 2025

    Pamela Wapnick, M.B.A.

    (Principal Financial Officer and Principal Accounting Officer)

    /s/ Jian Irish

    President, Chief Operating Officer and Director

    March 17, 2025

    Jian Irish, Ph.D., M.B.A.

    /s/ Sebastián Bernales

     

    Director

     

    March 17, 2025

    Sebastián Bernales, Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Eric Bjerkholt

    Director

    March 17, 2025

    Eric Bjerkholt, M.B.A.

    /s/ Willard Dere

    Director

    March 17, 2025

    Willard Dere, M.D.

    /s/ Juergen Eckhardt

    Director

    March 17, 2025

    Juergen Eckhardt, M.D., M.B.A.

     

     


    Get the next $MGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGX

    DatePrice TargetRatingAnalyst
    5/7/2024$10.00Buy
    H.C. Wainwright
    5/2/2024$16.00 → $6.00Overweight → Neutral
    JP Morgan
    3/5/2024Outperform
    TD Cowen
    3/5/2024$22.00Outperform
    BMO Capital Markets
    3/5/2024$16.00Overweight
    JP Morgan
    3/5/2024$23.00Buy
    Jefferies
    3/5/2024$21.00Buy
    Chardan Capital Markets
    3/5/2024$25.00Overweight
    Wells Fargo
    More analyst ratings

    $MGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

    New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026 Cash runway anticipated through 4Q 2027 EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that it has completed its corporate name change

    1/12/26 8:30:00 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

    EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference "Cracking the Code: Nucleic Acid Medicines Coming of Age" taking place December 8-10, 2025, in Boston, MA. Nature Conference "Cracking the Code: Nucleic Acid Medicines Coming of Age" Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Present

    12/1/25 7:00:00 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Metagenomi to Present at Jefferies Global Healthcare Conference in London

    EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A, President and Chief Executive Officer of Metagenomi, will be presenting at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:30 a.m. GMT. A live webcast will be available in the investor section of the company's website at https://ir.metagenomi.co/ and a replay will be available for a limited time at the same address. About Metagenomi Metagenomi is an in vivo genome editing

    11/17/25 8:00:00 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGX
    SEC Filings

    View All

    Metagenomi Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Metagenomi, Inc. (0001785279) (Filer)

    1/12/26 9:27:39 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Metagenomi Inc.

    10-Q - Metagenomi, Inc. (0001785279) (Filer)

    11/12/25 8:42:22 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Metagenomi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Metagenomi, Inc. (0001785279) (Filer)

    11/12/25 8:39:42 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thomas Brian C. sold $6,786 worth of shares (3,830 units at $1.77), decreasing direct ownership by 0.15% to 2,510,960 units (SEC Form 4)

    4 - Metagenomi, Inc. (0001785279) (Issuer)

    12/8/25 1:56:16 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Wein Matthew sold $353 worth of shares (199 units at $1.77), decreasing direct ownership by 0.17% to 115,031 units (SEC Form 4)

    4 - Metagenomi, Inc. (0001785279) (Issuer)

    12/8/25 1:51:33 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Wapnick Pamela sold $2,793 worth of shares (1,576 units at $1.77), decreasing direct ownership by 0.83% to 188,956 units (SEC Form 4)

    4 - Metagenomi, Inc. (0001785279) (Issuer)

    12/8/25 1:49:50 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Metagenomi with a new price target

    H.C. Wainwright initiated coverage of Metagenomi with a rating of Buy and set a new price target of $10.00

    5/7/24 6:26:47 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Metagenomi downgraded by JP Morgan with a new price target

    JP Morgan downgraded Metagenomi from Overweight to Neutral and set a new price target of $6.00 from $16.00 previously

    5/2/24 6:29:35 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Metagenomi

    TD Cowen initiated coverage of Metagenomi with a rating of Outperform

    3/5/24 7:45:11 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGX
    Financials

    Live finance-specific insights

    View All

    Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

    New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-owned MGX-001 hemophilia A program; pre-IND meeting for MGX-001 expected in 4Q 2025 with IND/CTA submissions expected in 4Q 2026 Organizational restructuring reduced workforce by 25%; Capital allocation strategy anticipated to extend cash runway into the 4Q 2027 Jian Irish, Ph.D., M.B.A., currently President and Chief Operating Officer, appointed as Chief Executive Officer; Brian Thomas, Ph.D., former Chief Executive Officer, continuing on Board of Directors and Dr. Willard Dere serving as new

    11/11/25 4:02:00 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

    Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced data from an ongoing preclinical

    9/3/24 4:05:00 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

    EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), which were previously subject to exclusive rights granted to Moderna, Inc. Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1

    5/1/24 4:00:00 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Metagenomi Inc.

    SC 13G - Metagenomi, Inc. (0001785279) (Subject)

    11/6/24 4:35:15 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Metagenomi Inc.

    SC 13G - Metagenomi, Inc. (0001785279) (Subject)

    5/10/24 6:40:45 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGX
    Leadership Updates

    Live Leadership Updates

    View All

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metagenomi Announces New Appointment to its Board of Directors

    EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025. "We are excited to welcome Eric to our Board of Directors," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an in

    1/15/25 8:55:00 AM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care